A method for determining the risk of an adverse pregnancy outcome for a woman is provided comprising the steps of measuring a level of TM7-H1 and optionally one or more of BVAB1, Sneathia amnii, and Prevotella cluster 2 in a vaginal sample obtained from the woman, and identifying the woman as having an increased risk for an adverse pregnancy outcome, or other adverse pregnancy outcomes, if the levels are increased compared to corresponding standard control levels. Methods for the prophylactic treatment of subjects identified as being at increased risk for an adverse pregnancy outcome are also provided.

Disclosed are methods for analyzing hormone profiles in a pregnant female to determine the pregnant females susceptibilty to spontaneous preterm delivery. In particular, disclosed are methods for identifying a pregnant female who is susceptible to spontaneous preterm delivery based on a formula including ratios of steroids in samples obtained from the pregnant female. Further, the methods can include treating the pregnant female identified susceptible to spontaneous preterm delivery.

Disclosed are methods for identifying a pregnant female who is susceptible to spontaneous preterm delivery. In particular, disclosed are methods for identifying a pregnant female who is susceptible to spontaneous preterm delivery based on ratios of steroids in samples obtained from the pregnant female.

Disclosed are methods for identifying a pregnant female who is susceptible to spontaneous preterm delivery. In particular, disclosed are methods for identifying a pregnant female who is susceptible to spontaneous preterm delivery based on ratios of steroids in samples obtained from the pregnant female. Further, the methods can include treating the pregnant female identified susceptible to spontaneous preterm delivery.

The present disclosure relates to biomarkers of preterm birth, biomarkers of term birth, and methods of use thereof. In particular, the present disclosure provides methods of determining whether a pregnant woman is at an increased risk for premature delivery. The present disclosure further provides methods for decreasing a pregnant woman's risk for premature delivery.

Kits and methods to distinguish between false and true labor are provided. The kits and methods can utilize differences in abundance and/or differences in the rate of change in abundance of B7-H2, SORC2, TF, C1-Esterase Inhibitor, Ran, IMDH1 and/or PGAM1, as markers of true labor.

Provided are diagnostic and/or screening tests, assays and devices for preeclampsia (PE). The diagnostic and/or screening tests, assays and devices include test antibodies for activin A and/or inhibin A. The PE diagnostic and/or screening tests, assays and devices are capable of detecting activin A and/or inhibin A in a sample at a concentration of less than about 60 pg/m L. Corresponding methods of diagnosing and/or screening for PE are provided.

Methods, kits and compounds are provided that relate to the diagnosis, treatment, and/or prevention of preeclampsia.

The present disclosure relates to proteomic biomarkers of spontaneous preterm birth, proteomic biomarkers of term birth, and methods of use thereof. In particular, the present disclosure provides tools for determining whether a pregnant subject is at an increased risk for premature delivery, as well as tools for decreasing a pregnant subject's risk for premature delivery.

The present invention relates to functional binding fragments comprising the minimal CSA-binding fragments of VAR2CSA and their use in identification and isolation of circulating trophoblast and/or fetal cells suitable for non-invasive prenatal diagnostic testing. Thus, the present invention describes methods of identifying and isolating trophoblast and/or fetal cells in a biological sample such as a maternal blood, and utilizing this for prenatal diagnostics.